Gema Ariceta Iraola Institucions de les que formen part Investigador/a principal Fisiopatologia renal Vall Hebron Institut de Recerca Email Gema Ariceta Iraola Email Institucions de les que formen part Investigador/a principal Fisiopatologia renal Vall Hebron Institut de Recerca
Línies de recerca Mechanisms of chronic renal disease progression and cardiovascular risk in pediatric patients with chronic renal disease Pediatric patients with chronic kidney disease (CKD) constitude a high risk group for cardiovascular disease (CVD) related to traditional and non-traditional risk factors. We are interested in studying the relationship between traditional CVD risk factors (obesity, overweight, anemia, dyslipemia, malnutrition, hypertension, and non-traditional CVD risk factors (homocysteine, asymmetric dymethylarginine (ADMA), FGF23, ultraselective protein C (PCR) and carotid intima-media thickness (cIMT) in children and adolescents with CKD, based on its severity and duration. Further, we are also interested in finding a biomarker to identify early in the disease, those patients with increased CVD risk and poor outcome. IP: Gema Ariceta Iraola Rare inhirited renal diseases Our group is focused in research in primary or inherited tubular renal diseases, such as Dent’s Disease, Bartter syndrome, Tubular Acidosis, Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, among others. Currently we are collaborating with other groups in Spain, within a research project named Renaltube the main purpose of which is to build a database while facilitating access to genotyping in order to improve the clinical and molecular knowledge of primary tubulopathies. Renaltube has a web-based approach with multilateral collaboration scheme that enhances the recruitment of data and promotes the understanding of underlying mechanisms of rare inherited diseases, defines more accurate diagnostic and follow-up criteria, develops new molecular techniques and will improve the overall care of the patients. Currently we are offering the analysis of 22 genes corresponding to 23 primary tubulopathies. After two years of activity Renaltube has collected data from 222 patients, the mayority from Spain and Latin America (85.3%). The most common tubulopathies are distal renal tubular acidosis (22.5%), and classical Bartter syndrome (19.3%) followed by familial hypomagesemia with hipercalciuria and nephrocalcinosis (15.7%), and Gitelman syndrome (15%). IP: Gema Ariceta Iraola, Anna Meseguer Navarro Projectes Caracterización de la respuesta inmune celular específica frente al virus Epstein-Barr en receptores de trasplante renal pediátrico (CRICE-VEB)). IP: - Col·laboradors: Gema Ariceta Iraola, Laura Donadeu Casassas, Delphine Kervella Entitat finançadora: Sociedad Española de Trasplantes Finançament: 20000 Referència: SET/AYUDAS.PROYECTOS/2023/LOPEZ Durada: 01/01/2024 - 31/12/2025 La variabilidad fenotípica en pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC) como oportunidad para entender las bases fisiopatológicas de la enfermedad y para la búsqueda de soluciones terapéuticas IP: Anna Meseguer Navarro Col·laboradors: Gema Ariceta Iraola, Gerard Cantero Recasens Entitat finançadora: Sociedad Española de Nefrología (S.E.N.) Finançament: 24000 Referència: SENEFRO/PROJECTES/2023/MESEGUER Durada: 27/11/2023 - 26/11/2025 RED NACIONAL DE LABORATORIOS DE FUNCION RENAL IP: Francesc Moreso Mateos Col·laboradors: Gema Ariceta Iraola, Joan López Hellin Entitat finançadora: Instituto de Salud Carlos III Finançament: 42900 Referència: PMP22/00119 Durada: 01/01/2023 - 31/12/2025 Biomarcadores, dianas y soluciones terapéuticas para mejorar el cuidado de pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC). IP: Gema Ariceta Iraola Col·laboradors: Hector Rios Duro, Gloria Mª Fraga Rodriguez, Julieta Torchia, Julieta Torchia Entitat finançadora: Instituto de Salud Carlos III Finançament: 202070 Referència: PI22/01946 Durada: 01/01/2023 - 31/12/2025 Paginació Pàgina actual 1 Page 2 Page 3 Pàgina següent › Última pàgina »
